Literature DB >> 10100718

Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.

B van Triest1, H M Pinedo, Y van Hensbergen, K Smid, F Telleman, P S Schoenmakers, C L van der Wilt, J A van Laar, P Noordhuis, G Jansen, G J Peters.   

Abstract

Thymidylate synthase (TS), a critical enzyme in the de novo synthesis of thymidylate, is an important target for fluoropyrimidines and folate-based TS inhibitors. In a panel of 13 nonselected human colon cancer cell lines, we evaluated the role of TS levels in sensitivity to 5-fluorouracil (5FU) and four folate-based TS inhibitors that have been introduced recently into the clinic: ZD1694 (Tomudex, Raltitrexed, TDX), GW1843U89 (GW), LY231514 (LY), and AG337 (Thymitaq, AG). Because the latter compounds have different transport and polyglutamylation characteristics, we also related these parameters with drug sensitivity, measured by the sulforhodamine B assay after 72 h of drug exposure. For 5FU, the IC50s varied from 0.8 to 43.0 microM. Leucovorin (LV) potentiated the activity of 5FU in only 4 of 13 cell lines. Sensitivity to folate-based TS inhibitors was variable; IC50s were in the range of: 5.3-59.0 nM TDX; 11.0-1570 nM LY; and 0.5-8.9 nM GW. Eleven of 13 cell lines had an IC50 for AG between 1.3 and 5.3 microM. Two cell lines were resistant to AG, Colo201 and SW1116, with IC50s of 27 and 29 microM, respectively. TS catalytic activity (conversion of dUMP to dTMP) varied from 62 to 777 pmol/h/10(6) cells. The number of FdUMP binding sites varied from 32 to 231 fmol/10(6) cells. Regression analysis showed a significant relation between TS catalytic activity and IC50s for 5FU and 5FU/LV. Kis for FdUMP showed a significant Spearman rank correlation with the IC50s of AG and GW. The role of antifolate transport, accumulation, and polyglutamylation was determined with [3H]methotrexate (MTX) as a reference compound. [3H]MTX influx via the reduced folate carrier varied from 18.6 to 150 fmol/10(6) cells/min. Folylpolyglutamate synthetase (FPGS) activity showed a range from 47 to 429 pmol/10(6) cells/h. A total of 24 h of [3H]MTX accumulation showed a 20-fold variation, from 1.2 to 21.8 pmol/10(6) cells. FPGS levels showed a Spearman rank positive correlation with cytotoxicity to TDX. In conclusion, in a heterogeneous nonselected human colon cancer cell line panel, the best predictor for sensitivity to 5FU and 5FU/LV was TS activity. Multiple sensitivity determinants were of importance for antifolate TS inhibitors, including FPGS activity and TS enzyme kinetics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100718

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

Review 1.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

2.  Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.

Authors:  Stefania Giudice; Luisa Benassi; Giorgia Bertazzoni; Eugenia Veratti; Daria Morini; Paola Azzoni; Maria P Costi; Alberto Venturelli; Silvia Pirondi; Stefania Seidenari; Cristina Magnoni
Journal:  Invest New Drugs       Date:  2011-09-01       Impact factor: 3.850

3.  Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase.

Authors:  Hiroaki Tsujimoto; Sayaka Tsukioka; Satoru Ono; Etsuko Sakamoto; Kazuki Sakamoto; Kohji Tsuta; Fumio Nakagawa; Hitoshi Saito; Junji Uchida; Mamoru Kiniwa; Masakazu Fukushima
Journal:  Oncol Lett       Date:  2010-09-17       Impact factor: 2.967

4.  Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.

Authors:  Osamu Kikuchi; Shinya Ohashi; Yukie Nakai; Shunsaku Nakagawa; Kazuaki Matsuoka; Takashi Kobunai; Teiji Takechi; Yusuke Amanuma; Masahiro Yoshioka; Tomomi Ida; Yoshihiro Yamamoto; Yasushi Okuno; Shin'ichi Miyamoto; Hiroshi Nakagawa; Kazuo Matsubara; Tsutomu Chiba; Manabu Muto
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

5.  Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).

Authors:  Godefridus J Peters; Kees Smid; Leonardo Vecchi; Ietje Kathmann; Dzjemma Sarkisjan; Richard J Honeywell; Nienke Losekoot; Osnat Ohne; Aric Orbach; Eran Blaugrund; Lak Shin Jeong; Young Bok Lee; Chang-Ho Ahn; Deog Joong Kim
Journal:  Invest New Drugs       Date:  2013-09-19       Impact factor: 3.850

6.  Predictive markers for the response to 5-fluorouracil therapy in cancer cells: Constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy.

Authors:  E M Saleh; R A El-Awady; N Anis
Journal:  Oncol Lett       Date:  2012-10-11       Impact factor: 2.967

7.  Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Ewa Majdanik; Maria Chosia; Dariusz Bielicki; Jozef Kladny; Mariusz Kaczmarczyk; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Virchows Arch       Date:  2009-05-15       Impact factor: 4.064

8.  Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.

Authors:  Bo Song; Yuan Wang; Matthew A Titmus; Galina Botchkina; Andrea Formentini; Marko Kornmann; Jingfang Ju
Journal:  Mol Cancer       Date:  2010-04-30       Impact factor: 27.401

9.  Identification of thymidylate synthase as a potential therapeutic target for lung cancer.

Authors:  K Takezawa; I Okamoto; S Tsukioka; J Uchida; M Kiniwa; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

Authors:  E Izbicka; A Diaz; R Streeper; M Wick; D Campos; R Steffen; M Saunders
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.